The National Institutes of Health is staring down a proposed $6 billion budget cut that could slash funding for biomedical research. The response from the drug industry’s largest lobbying group?
Let’s call it tepid.
“As we review the president’s budget proposal, we look forward to continuing to work with President Trump and Congress to improve American competitiveness and protect American jobs,” PhRMA spokeswoman Nicole Longo said in a statement. She added that the organization remains “committed to ensuring that policies support innovation and value to deliver this new era of medicines to patients.”
Biotech — to the extent it can be surveyed on Twitter — was not impressed.
“Those people are truly useless,” opined Michael Gilman, a serial entrepreneur now leading Arrakis Therapeutics.
“This is pathetic,” added John LaMattina, former head of R&D at Pfizer. “The new PhRMA head continues to be unimpressive.”
“Too bad PhRMA cannot muster the guts necessary to speak out,” tweeted Dr. Samuel Blackman, an oncologist and cancer researcher.
PhRMA’s bland response comes in stark contrast to statements from the Bill and Melinda Gates Foundation and the American Society of Clinical Oncology, which contained terms like “deeply troubled” and “devastate our nation’s research infrastructure.”